Results 61 to 70 of about 693,546 (355)

Isradipine Versus Placebo in Early Parkinson Disease

Annals of Internal Medicine, 2020
Background Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD). Objective To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical ...
T. Simuni
semanticscholar   +1 more source

Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease

Brain : a journal of neurology, 2021
The mechanisms responsible for the selective vulnerability of specific neuronal populations in Parkinson’s disease are poorly understood. Oxidative stress secondary to brain iron accumulation is one postulated mechanism.
G. Thomas, A. Zarkali, Mina Ryten, Karin Shmueli, A. Gil-Martínez, Louise-Ann Leyland, P. McColgan, J. Acosta-Cabronero, A. Lees, R. Weil   +9 more
semanticscholar   +1 more source

Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease

npj Parkinson's Disease
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, while secondary parkinsonism (SP) may be due to drugs, vascular, infectious, inflammatory, or even paraneoplastic etiologies. There is currently no biomarker that accurately distinguishes SP from PD.
Hong-Qi Yang, Ran Xin, Ning-Ning Che, Qiu-Huan Jiang, Shuai Chen, Si-Yuan Chen, Zhi-Kun Sun, Wei-Min Yang, Xue Li, Jian-Jun Ma, Jie-Wen Zhang, Rayaz A. Malik   +11 more
openaire   +3 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Pain-motor integration in the primary motor cortex in Parkinson's disease [PDF]

, 2017
In Parkinson's disease (PD), the influence of chronic pain on motor features has never been investigated. We have recently designed a technique that combines nociceptive system activation by laser stimuli and primary motor cortex (M1) activation through ...
Berardelli, Alfredo, Biasiotta, A, Cruccu, Giorgio, Di Santo, A, DI STASIO, Flavio, LA CESA, Silvia, Leone, Caterina, Marsili, Luca, Suppa, Antonio, Truini, Andrea   +9 more
core   +1 more source

A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease

npj Parkinson's Disease, 2021
Freezing of gait (FOG) in Parkinson’s disease (PD) causes severe patient burden despite pharmacological management. Exercise and training are therefore advocated as important adjunct therapies.
M. Gilat, Pieter Ginis, D. Zoetewei, Joni De Vleeschhauwer, Femke Hulzinga, N. D’cruz, A. Nieuwboer   +6 more
semanticscholar   +1 more source

Interplay between RNA‐protein interactions and RNA structures in gene regulation

FEBS Open Bio, EarlyView.
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko, Mauro Scaravilli, Minna‐Liisa Änkö   +2 more
wiley   +1 more source

Abnormal ECG Findings in Athletes: Clinical Evaluation and Considerations. [PDF]

, 2019
PURPOSE OF REVIEW: Pre-participation cardiovascular evaluation with electrocardiography is normal practice for most sporting bodies. Awareness about sudden cardiac death in athletes and recognizing how screening can help identify vulnerable athletes have
A Biffi, A Biffi, A D’Silva, A D’Silva, A Magalski, A Malhotra, A Malhotra, A Malhotra, A Merghani, A Morshedi-Meibodi, A Pelliccia, A Pelliccia, A Zaidi, A Zaidi, A Zorzi, A Zorzi, A Zorzi, AD Desai, AL Aro, AL Rao, AO Usoro, BJ Maron, BJ Maron, C Antzelevitch, C Calore, C Daubert, C Miles, D Corrado, D Corrado, D Corrado, D Corrado, F D’Ascenzi, F Migliore, F Schnell, FI Marcus, G Finocchiaro, G Malfatto, G Mcclean, GJ Klein, GJ Klein, H Dhutia, H Morita, HUH Virk, J Basu, J Ehtisham, J Marek, J Novak, J Pei, J Steinfurt, JA Drezner, JA Drezner, KG Harmon, KM Park, L Calò, L Verdile, M Brosnan, M Papadakis, M Papadakis, M Sadron Blaye-Felice, MAE Haukilahti, Mark Abela, MG Wilson, MI Cohen, MJ Ackerman, MJ Brosnan, N Chandra, N Panhuyzen-goedkoop, N Sheikh, P Banankhah, PG Postema, PT Matusik, RE Bent, RE Eckart, S Gati, S Kapa, S Masrur, S Peters, S Sharma, S Viskin, Sanjay Sharma, SEE Page, T Senturk, X Li, YH Lee   +83 more
core   +1 more source

CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease

Journal of Neuroinflammation, 2011
Background Parkinson's disease is characterized by a progressive loss of dopaminergic neurons in the substantia nigra. The cause of the neurodegeneration is unknown.
Hudson Charles E, Bachstetter Adam D, Pabon Mibel M, Gemma Carmelina, Bickford Paula C   +4 more
doaj   +1 more source

Understanding fatigue in progressive supranuclear palsy

Scientific Reports, 2021
Fatigue is a common and disabling non-motor symptom (NMS) of Parkinson’s disease (PD); however, it has been poorly understood in patients with progressive supranuclear palsy (PSP).
Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho   +4 more
doaj   +1 more source